Recently, a Phase II, randomized-controlled trial (MOVES-PD), testing the effect of the glucosylceramide synthase inhibitor Venglustat in GBA1-PD patients, did not meet its primary endpoint, and showed paradoxical worsening of motor symptoms in mild GBA1-PD treated with Venglustat22. Here, UGCG is linked to Parkinson disease.